SPRC
vs
S&P 500
SPRC
S&P 500
Over the past 12 months, SPRC has underperformed S&P 500, delivering a return of -93% compared to the S&P 500's +12% growth.
Stocks Performance
SPRC vs S&P 500
Performance Gap
SPRC vs S&P 500
Performance By Year
SPRC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Scisparc Ltd
Glance View
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.